# 2025年12月14日 - 专业文献速递

本期速递为您整理了最新的科研文献及AI评价，每一篇文献都包含了详细的元数据、原文摘要、中文翻译和AI的专业点评，敬请参考。

---

## 1. 运动与肾脏健康：核心课程2026

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41389078)
**期刊：** American journal of kidney diseases : the official journal of the National Kidney Foundation
**PMID：** 41389078
**DOI：** 10.1053/j.ajkd.2025.09.014

### 第一部分 原文与翻译

**英文原标题：** Exercise and Kidney Health: Core Curriculum 2026.

> **英文摘要：**
> Exercise triggers complex effects on kidney physiology that vary with intensity, duration, and environmental conditions. While moderate physical activity improves cardiovascular and renal outcomes, intense or prolonged exertion, particularly in endurance sports, can lead to acute kidney injury. Adaptations in kidney physiology during exercise include reduced plasma flow, altered glomerular filtration, and hormone-mediated fluid retention. These changes are protective but may become maladaptive with dehydration, heat stress, or excessive fluid intake. High-intensity exercise increases oxidative stress and proteinuria, while ultramarathon participation may cause transient creatinine elevation from muscle breakdown, complicating acute kidney injury diagnosis. Prevention strategies include individualized hydration plans, electrolyte replacement, and avoidance of nonsteroidal anti-inflammatory drugs. In special populations, such as children with chronic kidney disease or patients receiving dialysis, structured exercise enhances quality of life and physical function when implemented safely. Clinicians must balance the benefits of exercise with kidney-related risks, promote safe training practices, and recognize early signs of exertional complications to optimize renal and overall health in physically active individuals. This core curriculum reviews the physiology of exercise on kidney function and provides evidence-based strategies for patient counseling and risk reduction.

> **中文摘要：**
> 运动会引发对肾脏生理产生复杂影响，其效应受运动强度、持续时间及环境条件的影响。适度的身体活动可改善心血管与肾脏结局，而剧烈或长时间的体力消耗，尤其是在耐力运动中，可能导致急性肾损伤。运动过程中肾脏生理的适应包括血浆流量减少、肾小球滤过改变以及由激素介导的体液潴留。这些改变具有保护作用，但在脱水、热应激或过量摄入液体时可能变为不良反应。高强度运动会增加氧化应激和蛋白尿，而参加超级马拉松可能因肌肉分解导致肌酐暂时升高，从而使急性肾损伤的诊断复杂化。预防策略包括个体化的补液计划、电解质补充以及避免使用非甾体抗炎药。在特殊人群中，如慢性肾病儿童或透析患者，若安全实施系统化运动，可提高生活质量和身体功能。临床医生必须平衡运动益处与肾脏相关风险，促进安全训练实践，并识别运动相关并发症的早期信号，以优化身体活动个体的肾脏及整体健康。本核心课程综述了运动对肾功能的生理影响，并提供了基于证据的患者教育与风险降低策略。

### 第二部分 AI 大师评价

本文系统回顾了运动对肾脏生理功能的影响，强调适度运动的益处及极端运动的潜在风险。作者从血流动力学、滤过功能、激素调节及氧化应激等方面阐述机制，并结合临床人群提出个体化预防策略。文章的创新在于将运动生理与肾脏医学实践相结合，为慢性肾病及透析患者运动管理提供循证指导。其局限在于缺乏具体人群数据及长期随访证据，未来需通过临床研究验证推荐策略的有效性。

---

## 2. 基于电子健康记录的脓毒症与脓毒性休克病例识别：一个开源工作流程及不同判定标准下的队列比较

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41388426)
**期刊：** Critical care (London, England)
**PMID：** 41388426
**DOI：** 10.1186/s13054-025-05749-1

### 第一部分 原文与翻译

**英文原标题：** Sepsis and septic shock case identification from electronic health records: an open-source workflow and comparison of cohorts by criteria.

> **英文摘要：**
> BACKGROUND: Deploying clinical criteria to identify patients with sepsis from the electronic health record is challenging. We sought to build an open-source data workflow for sepsis and septic shock case identification using three distinct criteria and assess the identified cohorts.
> 
> METHODS: We developed a workflow from raw data queries through case identification using the Centers for Disease Control and Prevention Adult Sepsis Event (CDC ASE), Sepsis-3, and International Classification of Diseases criteria. The workflow was then applied to patient encounters between 2012 and 2024 across 25 emergency departments and hospitals in an integrated health system. Separate cohorts of sepsis and septic shock patients by criteria were derived, restricted to a patient's first sepsis encounter, and compared. Pairwise agreement was evaluated with Cohen's kappa (κ) and Jaccard index.
> 
> RESULTS: Our programming code for the complete workflow is available on a public platform. We identified 302,112 patients with sepsis and 59,043 with septic shock who met one or more of the three criteria. Multiple criteria were satisfied for only 35% of patients meeting at least one sepsis criterion and 45% of patients meeting at least one septic shock criterion. Pairwise agreement was the highest between CDC ASE and Sepsis-3 criteria for both sepsis (κ = 0.39, Jaccard index = 0.31) and septic shock (κ = 0.53, Jaccard index = 0.37). Characteristics and outcomes of patients differed across cohorts identified with the three criteria. Patients meeting both CDC ASE and Sepsis-3 criteria for sepsis and septic shock were more severely ill and had high in-hospital mortality incidence.
> 
> CONCLUSIONS: Our open-source workflow is useful for individuals seeking to build and analyze sepsis and septic shock cohorts. Agreement between case criteria was fair to moderate. Clinicians, researchers, and quality improvement practitioners who identify patient cohorts with sepsis and septic shock retrospectively should consider applying multiple criteria.

> **中文摘要：**
> 背景：使用电子健康记录（EHR）的临床标准来识别脓毒症患者具有挑战性。我们旨在构建一个用于脓毒症和脓毒性休克病例识别的开源数据工作流程，基于三种不同的标准，并评估所得队列。
> 
> 方法：我们开发了一个从原始数据查询到病例识别的完整工作流程，采用美国疾病控制与预防中心成人脓毒症事件标准（CDC ASE）、Sepsis-3 标准以及国际疾病分类（ICD）标准。随后，这一工作流程被应用于2012年至2024年间一个综合性医疗体系内25家急诊科及医院的患者就诊记录。根据不同标准分别提取脓毒症和脓毒性休克患者的独立队列，仅限于患者首次脓毒症事件，并进行了比较。使用 Cohen’s kappa（κ）和 Jaccard 指数评估两两标准之间的一致性。
> 
> 结果：该完整工作流程的编程代码已在公共平台上开放获取。我们共识别出302,112例符合至少一种标准的脓毒症患者，以及59,043例脓毒性休克患者。仅有35%的脓毒症患者和45%的脓毒性休克患者同时满足多项标准。CDC ASE 与 Sepsis-3 标准之间的一致性最高，脓毒症的 κ 值为0.39、Jaccard 指数为0.31；脓毒性休克的 κ 值为0.53、Jaccard 指数为0.37。按不同标准识别的队列在患者特征与结局方面存在差异。符合 CDC ASE 与 Sepsis-3 双重标准的脓毒症和休克患者病情更重，院内死亡率更高。
> 
> 结论：该开源工作流程可为构建与分析脓毒症及脓毒性休克队列的人员提供实用工具。不同病例标准间的一致性处于一般至中等水平。临床医生、研究者及质量改进工作人员在回顾性识别脓毒症与脓毒性休克患者队列时，应考虑同时应用多种标准。

### 第二部分 AI 大师评价

本研究旨在解决从电子健康记录中准确识别脓毒症与脓毒性休克病例的难题，开发了一个基于 CDC ASE、Sepsis-3 和 ICD 三大标准的开源自动化工作流程。该系统在实际临床数据库中进行了大规模验证，揭示三种标准在病例识别上的一致性仅处于较低至中等水平。结果为不同诊断标准下的队列构成及预后差异提供了新证据。研究的创新在于其开放资源和可复用性，但局限在于依赖单一健康系统的数据。

---

## 3. 复苏后血管扩张性休克的管理：目标、策略与结局

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41388310)
**期刊：** Critical care (London, England)
**PMID：** 41388310
**DOI：** 10.1186/s13054-025-05794-w

### 第一部分 原文与翻译

**英文原标题：** Management of post-resuscitation vasoplegic shock: targets, strategies and outcomes.

> **英文摘要：**
> Despite advancements in management of cardiac arrest, mortality remains high due to extended brain injury, severe myocardial dysfunction and systemic inflammatory response leading to refractory shock. Accordingly, in addition to fluid therapy, vasopressors are often required after return of spontaneous circulation (ROSC) to counteract vasoplegia and to preserve end-organ perfusion. In this narrative review, we discuss the current evidence on the use of adrenergic and non-adrenergic vasopressors after cardiac arrest. Currently, the recommended target is a mean arterial pressure (MAP) of at least 60-65 mmHg and there is little evidence to support aiming for a MAP above 70 mmHg. Norepinephrine remains the most commonly used vasopressor to manage arterial hypotension after ROSC. Outside of clinical research, there is insufficient data to support the routine use of vasopressin, angiotensin II or non-selective nitric oxide inhibitors. Multimodal, real-time hemodynamic monitoring may help clinicians identify the predominant circulatory phenotype and guide vasopressor choice, dosing and timing to reduce the risk of adverse events. More research is needed to establish the role of a balanced vasopressor approach in the management of post-resuscitation vasoplegic shock.

> **中文摘要：**
> 尽管心脏骤停管理取得了进展，但由于持续的脑损伤、严重的心肌功能障碍以及导致难治性休克的全身炎症反应，病死率仍然较高。因此，除液体治疗外，在自主循环恢复（ROSC）后常需使用血管加压药以对抗血管扩张并维持重要器官灌注。在本综述中，我们讨论了心脏骤停后肾上腺素能与非肾上腺素能血管加压药的最新应用证据。目前推荐的目标是平均动脉压（MAP）至少维持在60–65 mmHg，且缺乏支持将目标设定在70 mmHg以上的证据。去甲肾上腺素仍是ROSC后控制动脉低血压最常使用的血管加压药。在临床研究之外，尚无充分数据支持常规使用加压素、血管紧张素II或非选择性一氧化氮抑制剂。多模态、实时血流动力学监测可能有助于临床医生识别主要的循环表型，并指导血管加压药的选择、剂量和使用时机，从而降低不良事件风险。仍需进一步研究以确定平衡性血管加压策略在复苏后血管扩张性休克管理中的作用。

### 第二部分 AI 大师评价

该综述聚焦于复苏后血管扩张性休克的管理策略，系统总结了肾上腺素能与非肾上腺素能加压药的应用证据及推荐目标。作者强调维持平均动脉压60–65 mmHg为当前合理目标，并指出去甲肾上腺素仍是首选药物。研究提出多模态血流动力学监测有助于优化个体化治疗，减少不良事件。本综述的创新性在于整合当前循证观点并提出平衡加压策略的潜力，但同时也指出现有证据有限，需要更多临床研究验证。

---

## 4. MRSA 中的万古霉素异质耐药性（hVISA）与治疗失败相关，并支持修订后的 PAP-AUC 阈值。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41387691)
**期刊：** Nature communications
**PMID：** 41387691
**DOI：** 10.1038/s41467-025-66118-8

### 第一部分 原文与翻译

**英文原标题：** Vancomycin heteroresistance (hVISA) in MRSA links to treatment failure and supports a revised PAP-AUC threshold.

> **英文摘要：**
> Heteroresistance to vancomycin among methicillin-resistant Staphylococcus aureus (MRSA) remains a diagnostic and therapeutic problem in clinical microbiology. In this prospective cohort study of 842 adult patients with MRSA bacteremia in S. Korea, we investigate the prevalence, risk factors, and clinical implications of the heteroresistant vancomycin-intermediate S. aureus (hVISA) phenotype. The hVISA phenotype is detected in 22% of cases. Multivariable regression analysis reveals strong positive associations between hVISA and hospital-acquired infection, prior anti-MRSA therapy, vancomycin exposure, and particularly vancomycin MIC (odds ratio 15.2 per 1 mg/L increase, p < 0.001). Strikingly, patients infected with hVISA strains have a lower 90-day mortality compared to those with fully susceptible strains (hazard ratio 0.66, p = 0.019), suggesting a possible trade-off between resistance and virulence. However, in hVISA strains treated with vancomycin, outcomes reverse: mortality more than doubled (HR 2.5, p < 0.001), bacteremia persisted longer, and relapse rates increased fivefold. Using maximally selected rank statistics, we identify a PAP-AUC threshold of 0.65 as the first clinically derived breakpoint predictive of mortality risk, providing an actionable definition of vancomycin heteroresistance. These findings underscore the clinical relevance of hVISA, and support routine testing for heteroresistance to inform treatment decisions.

> **中文摘要：**
> 甲氧西林耐药金黄色葡萄球菌（MRSA）对万古霉素的异质耐药性在临床微生物学中仍是诊断和治疗的难题。在这项包含842例韩国MRSA菌血症成年患者的前瞻性队列研究中，我们探讨了异质性万古霉素中介型金黄色葡萄球菌（hVISA）表型的流行率、危险因素及其临床意义。研究发现，22%的病例检测到hVISA表型。多变量回归分析显示，hVISA与医院获得性感染、既往抗MRSA治疗、万古霉素暴露，尤其是万古霉素MIC（每增加1 mg/L，优势比为15.2，p < 0.001）之间存在显著正相关。值得注意的是，感染hVISA菌株的患者与感染完全敏感菌株者相比，其90天死亡率较低（风险比0.66，p = 0.019），提示耐药性与毒力之间可能存在权衡。然而，在接受万古霉素治疗的hVISA感染患者中，结局出现逆转：死亡率超过两倍（HR=2.5，p < 0.001），菌血症持续时间更长，复发率增加五倍。通过最大秩统计分析，我们确定了0.65的PAP-AUC阈值，作为首个临床推导的可预测死亡风险的分界点，为万古霉素异质耐药提供了可操作的定义。这些发现强调了hVISA的临床相关性，并支持常规检测异质耐药性以指导治疗决策。

### 第二部分 AI 大师评价

该研究系统评估了韩国MRSA菌血症患者中万古霉素异质耐药表型（hVISA）的流行率及其临床影响，通过大样本前瞻性队列并结合多变量模型揭示了关键危险因素。研究发现hVISA虽与较低的总体死亡率有关，但在接受万古霉素治疗时反而导致更高的死亡和复发风险，提示治疗策略需调整。其提出的0.65 PAP-AUC阈值为首个临床验证的异质耐药分界值，具有重要实践意义。研究的主要创新在于构建了可量化的临床决策依据，但仍需在不同地区和菌株背景下进一步验证其普适性。

---

## 5. 对940例从未吸烟者肺癌的微生物组分析显示缺乏临床相关性关联。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41387456)
**期刊：** Nature communications
**PMID：** 41387456
**DOI：** 10.1038/s41467-025-66780-y

### 第一部分 原文与翻译

**英文原标题：** Microbiome analysis of 940 lung cancers in never-smokers reveals lack of clinically relevant associations.

> **英文摘要：**
> In spite of the growing interest in the microbiome in human cancer, there are currently only small-scale lung cancer microbiome studies conducted directly on tissue. As part of the Sherlock-Lung study, we studied the microbiomes of 940 lung cancers (4090 samples) in never smokers (LCINS) directly from lung tissue using three data types: 16S rRNA gene sequencing (16S), whole-genome sequencing (WGS) with paired blood, and RNA-seq. We observe very low biomass and few microbiome associations in LCINS using 16S and WGS tissue. Using RNA-seq, we observe more total microbial reads, and decreased relative abundance of several commensal bacteria at the genus and species levels in tumors relative to paired normal lung tissue. Among all datasets, we see no consistent associations between the lung tissue microbiome, or circulating bacterial DNA, and any available demographic and clinical features, including age, sex, genetic ancestry, second-hand tobacco smoking exposure, LCINS histology, stage, and overall survival. We also observe no microbiome associations with any human genomic alterations within the same samples. Every null result should be interpreted with caution given the possibility of future methodological breakthroughs. However, all together, using multiple data types in nearly 1000 patients, we find no substantive role for the lung cancer microbiome in treatment-naïve LCINS.

> **中文摘要：**
> 尽管人们对人类癌症中的微生物组兴趣日益增长，但目前仅有少量直接基于组织的肺癌微生物组研究。作为Sherlock-Lung研究的一部分，我们利用三种数据类型——16S rRNA基因测序（16S）、与配对血液的全基因组测序（WGS）以及RNA测序（RNA-seq）——直接分析了940例从未吸烟者（LCINS）的肺癌组织微生物组（共4090个样本）。我们发现，在16S和WGS组织数据中，LCINS的生物量极低，微生物组关联也很少。使用RNA测序时，我们观察到总微生物读数较多，且在肿瘤组织中，相较于配对的正常肺组织，多个共生菌属和种水平的相对丰度降低。在所有数据集中，我们未发现肺组织微生物组或循环细菌DNA与任何可用的人口学及临床特征之间存在一致关联，包括年龄、性别、遗传祖源、二手烟暴露、LCINS的组织学类型、分期以及总体生存率。同样，我们也未观察到在相同样本中微生物组与任何人类基因组改变存在关联。鉴于未来方法学突破的可能性，每一个“无显著结果”都应谨慎解读。然而，总的来说，通过在近1000名患者中使用多种数据类型，我们未发现微生物组在未经治疗的LCINS中具有实质性作用。

### 第二部分 AI 大师评价

本研究系统地评估了从未吸烟者肺癌的组织微生物组特征，结合16S测序、全基因组测序和RNA测序三种数据类型，覆盖近千例患者。结果显示，组织样本中微生物生物量极低，且未发现与临床特征或基因组变化的稳定相关性。该研究以大样本和多组学方式为该领域提供了坚实证据，表明肺癌组织微生物组可能并非主要病理驱动因素。然而，作者也谨慎指出，未来方法学进展可能揭示目前无法检测到的微弱效应。

---

## 6. G-CSF/NAMPT 信号通路驱动中性粒细胞功能障碍并增加癌症患者的细菌感染易感性

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41387444)
**期刊：** Nature communications
**PMID：** 41387444
**DOI：** 10.1038/s41467-025-67471-4

### 第一部分 原文与翻译

**英文原标题：** G-CSF/NAMPT signaling drives neutrophil dysfunction and enhances bacterial infection susceptibility in cancer patients.

> **英文摘要：**
> Despite advancements in cancer therapies, bacterial complications remain a major challenge, delaying treatment and worsening outcomes. While immunosuppressive therapies and prolonged hospitalizations contribute, they do not fully explain the elevated infection risk in cancer patients. Here we show that tumors producing high levels of granulocyte colony-stimulating factor (G-CSF) promote the persistence of Gram-negative pathogens in head and neck squamous cell carcinoma due to neutrophil reprogramming. Mechanistically, we identify tumor-driven activation of the G-CSF / nicotinamide phosphoribosyltransferase (NAMPT) signaling axis in neutrophil progenitors, resulting in impaired antibacterial functions, such as phagocytosis and neutrophil extracellular traps formation, and development of tissue-damaging neutrophil subsets. This disrupts lung tissue integrity and facilitates bacterial persistence. Importantly, targeting the G-CSF/NAMPT pathway prevents the generation of dysfunctional neutrophils and improves bacterial clearance in vivo. Our findings reveal tumor-induced, NAMPT-dependent neutrophil reprogramming as a central driver of compromised antimicrobial defenses in cancer. Therapeutic strategies aimed at modulating G-CSF/NAMPT signaling could enhance infection control and survival for cancer patients.

> **中文摘要：**
> 尽管癌症治疗取得了进展，细菌并发症仍然是主要挑战，会延迟治疗并导致预后恶化。虽然免疫抑制性治疗和长期住院是重要原因，但它们无法完全解释癌症患者感染风险升高的现象。本研究表明，分泌高水平粒细胞集落刺激因子（G-CSF）的肿瘤可通过中性粒细胞重编程，促进头颈部鳞状细胞癌中革兰阴性菌的持续存在。在机制上，我们鉴定出肿瘤驱动的 G-CSF / 烟酰胺磷酸核糖转移酶（NAMPT）信号轴在中性粒细胞前体中的激活，导致其抗菌功能受损，如吞噬作用与中性粒细胞胞外陷阱（NETs）形成能力下降，并诱导组织损伤性中性粒细胞亚群的产生。该过程破坏了肺组织完整性，促进了细菌的持续存在。重要的是，靶向 G-CSF/NAMPT 通路可防止功能障碍性中性粒细胞的生成，并在体内改善细菌清除。我们的研究揭示了肿瘤诱导、依赖 NAMPT 的中性粒细胞重编程是癌症中抗菌防御受损的核心驱动因素。旨在调控 G-CSF/NAMPT 信号的治疗策略可能有助于增强感染控制并提高癌症患者的生存率。

### 第二部分 AI 大师评价

本研究聚焦于癌症患者易感细菌感染的关键免疫机制，揭示了由肿瘤驱动的 G-CSF/NAMPT 信号轴在中性粒细胞发育阶段的异常激活会造成抗菌功能障碍。作者通过机制研究和体内实验明确指出该通路的靶向干预可恢复中性粒细胞功能并改善感染清除。这一发现为连接肿瘤免疫代谢与感染易感性的分子机制提供了新的证据，并为癌症患者感染防治策略提供了潜在的治疗靶点。研究的创新性在于揭示 NAMPT 依赖性中性粒细胞重编程的新作用环节，但临床转化仍需进一步验证。

---

## 7. 铜绿假单胞菌 RpoN 对吞噬细胞代谢产物伊他康酸的截留促进其成功的肺部感染。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41387428)
**期刊：** Nature communications
**PMID：** 41387428
**DOI：** 10.1038/s41467-025-67153-1

### 第一部分 原文与翻译

**英文原标题：** Sequestration of the phagocyte metabolite itaconate by Pseudomonas aeruginosa RpoN promotes successful pulmonary infection.

> **英文摘要：**
> Inhaled opportunistic pathogens such as Pseudomonas aeruginosa actively modify gene expression to meet the challenges of a new environment. In the infected airway the bacteria must respond to the immunometabolite itaconate, which is abundantly produced by macrophages and has anti-inflammatory and anti-oxidant functions that protect the host from airway damage and causes toxicity to bacteria. As a dicarboxylate that targets cysteine residues, itaconate can modify both bacterial and host proteins often altering metabolic activity. We demonstrate that itaconate promotes a global metabolic response in P. aeruginosa by enhancing the activity of the major alternative transcription factor RpoN. Itaconate is actively transported into the bacteria, induces σ rpoN expression and covalently binds cysteine residues 218 and 275 on RpoN helping to neutralize its toxicity. The S-itaconated RpoN exhibits a gain of function driving increased glucose catabolism and enhanced utilization of the bioenergetically efficient Entner-Doudoroff pathway. Thus, the accumulation of itaconate in the infected airway promotes the adaptation of P. aeruginosa to the lung by optimizing its metabolic activity and ability to cause pneumonia.

> **中文摘要：**
> 吸入性的机会性感染病原体，如铜绿假单胞菌，会主动调节基因表达以应对新环境的挑战。在受感染的气道中，细菌必须应对免疫代谢物伊他康酸，该物质由巨噬细胞大量产生，具有抗炎和抗氧化功能，可保护宿主免受气道损伤，同时对细菌具有毒性。作为一种靶向半胱氨酸残基的二羧酸，伊他康酸可以修饰细菌和宿主蛋白，常常改变代谢活性。我们证明，伊他康酸通过增强主要替代转录因子 RpoN 的活性，在铜绿假单胞菌中引发全局性的代谢反应。伊他康酸被主动转运进入细菌中，诱导 σ rpoN 表达，并与 RpoN 的第 218 位和第 275 位半胱氨酸残基共价结合，从而帮助中和其毒性。S-伊他康酰化的 RpoN 表现出功能获得型改变，促进葡萄糖分解代谢的增加，并增强对生物能效更高的 Entner–Doudoroff 途径的利用。因此，感染气道中伊他康酸的积累通过优化代谢活性和致病能力，促进了铜绿假单胞菌对肺部环境的适应。

### 第二部分 AI 大师评价

本研究揭示了宿主免疫代谢产物伊他康酸与铜绿假单胞菌转录调控因子 RpoN 之间的化学与功能交互。作者通过分子与代谢水平的实验，发现伊他康酸不仅被细菌主动吸收，还能修饰 RpoN，改变其代谢调控特性，从而促进细菌在肺部感染中的生存与适应。该发现深化了对病原体代谢适应机制的理解，并揭示了宿主代谢物可能被病原体“劫持”以增强致病性的机制。尽管研究揭示了重要机制，但其在体内不同感染阶段的动态作用仍有待进一步探索。

---

## 8. 应激诱导的有毒基因组R环促进生物膜细胞外基质的形成

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41387400)
**期刊：** Nature communications
**PMID：** 41387400
**DOI：** 10.1038/s41467-025-66315-5

### 第一部分 原文与翻译

**英文原标题：** Stress-induced toxic genomic R-loops support biofilm extracellular matrix formation.

> **英文摘要：**
> Self-aggregation into biofilms is a bacterial stress response that promotes antimicrobial resistance because biofilms comprise viscous extracellular polymeric matrices that impede antimicrobial diffusion. Extracellular DNA (eDNA) is typically a principal component of the biofilm matrix. Here we show that persistent R-loops, which are three-stranded nucleic acid structures consisting of single DNA and a DNA:RNA hybrid, contribute to the viscoelastic behaviour of eDNA in Pseudomonas aeruginosa biofilms. The RNA strands are inserted throughout the genome by the strand exchange protein RecA, at locations in the genome distant from the site of their own transcription i.e. in trans. R-loop formation creates genomic instability in bacterial cells that subsequently die and release R-loops. These events appear to occur as part of a programmed cell death pathway, which is activated by the stringent stress response. The released R-loops become building blocks of the viscoelastic extracellular matrix, for the benefit of the remaining population. Our results indicate that R-loops facilitate the formation of the viscoelastic eDNA matrix in the context of bacterial stress responses, and that interfering with the R-loops may provide a broadly effective strategy for biofilm control.

> **中文摘要：**
> 细菌通过自聚集形成生物膜是一种应激反应，有助于抗菌耐受性，因为生物膜由黏稠的细胞外聚合物基质构成，从而阻碍抗菌剂的扩散。细胞外DNA（eDNA）通常是生物膜基质的主要成分。我们在此显示，持续存在的R环——由单链DNA和DNA:RNA杂交链形成的三链核酸结构——有助于铜绿假单胞菌生物膜中eDNA的粘弹性行为。RNA链通过链交换蛋白RecA被插入至整个基因组中，位置远离其自身的转录位点，即以反式方式进行。R环的形成会导致细菌细胞的基因组不稳定性，这些细胞随后死亡并释放R环。这些事件似乎是程序性细胞死亡通路的一部分，而该通路由严格的应激反应激活。释放的R环成为粘弹性细胞外基质的构建模块，从而使剩余的细胞群体受益。我们的结果表明，R环在细菌应激反应背景下促进了粘弹性eDNA基质的形成，而干扰R环的形成可能为控制生物膜提供一种具有广泛适用性的策略。

### 第二部分 AI 大师评价

本文揭示了R环结构在细菌生物膜形成中的新功能，即在应激反应下形成的有毒基因组R环可作为eDNA基质的结构性组分。研究通过铜绿假单胞菌模型，阐明了RecA介导的反式R环插入机制以及其导致的基因不稳定和细胞死亡过程。该过程释放出的R环成为生物膜粘弹性基质的组成部分，从而增强群体生存能力。该研究为理解应激诱导的生物膜形成提供了分子层面的新机制，并提示针对R环的干预可能成为抗生物膜治疗的新策略。

---

## 9. 未来十年结节病的治疗展望

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41237809)
**期刊：** Seminars in respiratory and critical care medicine
**PMID：** 41237809
**DOI：** 10.1055/a-2746-4508

### 第一部分 原文与翻译

**英文原标题：** Treatment of Sarcoidosis Over the Next Decade.

> **英文摘要：**
> Sarcoidosis is an enigmatic, multisystem inflammatory disorder characterized by the formation of non-necrotizing granulomas in affected organs. Sarcoidosis may be self-limited or spontaneously resolve in up to two-thirds of individuals, but 10% to 30% develop a more chronic syndrome requiring long-term treatment. Most individuals will require treatment at some point during the course of the disease. Currently, guidelines recommend treatment in those at risk of future morbidity or organ dysfunction to preserve the quality of life. Careful identification of those likely to benefit from treatment is critical, as current agents are cumbersome to monitor and all have adverse effects. There is a lack of validated prognostic markers to identify those at risk for poor outcomes, but identifying characteristic manifestations of severe disease early can assist with treatment planning. While corticosteroids have been central to the treatment of sarcoidosis, newer data have challenged the current treatment paradigm of steroids as first-line agents. Recent and ongoing clinical trials may provide evidence for individualized approaches centered on shared decision-making with patients, as balancing the benefits of treatment must always be weighed with the potential for toxicity. This paper will provide an update on current treatment paradigms, new therapeutic strategies, and potential novel agents on the horizon while highlighting the existing challenges and barriers to progress.

> **中文摘要：**
> 结节病是一种神秘的多系统炎症性疾病，其特征是在受累器官中形成非坏死性肉芽肿。结节病可能为自限性疾病，或在多达三分之二的患者中可自行缓解，但有10%至30%的患者会发展为需要长期治疗的慢性综合征。多数患者在疾病过程中某个阶段需要接受治疗。目前的指南建议，对于存在未来发病或器官功能障碍风险、需要维持生活质量的患者，应予以治疗。准确识别可能从治疗中获益的患者至关重要，因为当前的药物监测繁琐，且均存在不良反应。目前缺乏验证的预后标志物来确定有不良结局风险的患者，但早期识别严重疾病的特征性表现有助于制定治疗计划。虽然糖皮质激素一直是结节病治疗的核心，但新近研究数据对将激素作为一线治疗的传统模式提出了挑战。近期及正在进行的临床试验可能为以患者共同决策为中心的个体化治疗策略提供证据，因为在治疗中必须权衡疗效与潜在毒性之间的平衡。本文将更新当前的治疗模式，探讨新的治疗策略及潜在的新型药物，并强调现有的挑战与进展障碍。

### 第二部分 AI 大师评价

本文旨在综述未来十年结节病治疗策略的发展趋势，重点分析糖皮质激素治疗模式的演变及替代疗法的潜在前景。作者强调了个体化治疗与患者共同决策的重要性，同时讨论了缺乏有效预后标志物所带来的挑战。文章具有前瞻性，凸显临床试验在优化治疗方案中的关键作用。其创新之处在于整合最新研究证据以重塑治疗范式，但目前仍受限于长期疗效与安全性数据的不足。

---

速递结束，祝您工作愉快！